A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of 3 Concentrations of Topically Applied BBI-4000 (Sofpironium Bromide) Gel in Subjects With Axillary Hyperhidrosis

Trial Profile

A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of 3 Concentrations of Topically Applied BBI-4000 (Sofpironium Bromide) Gel in Subjects With Axillary Hyperhidrosis

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2018

At a glance

  • Drugs Sofpironium bromide (Primary)
  • Indications Hyperhidrosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Brickell Biotech
  • Most Recent Events

    • 20 Feb 2018 Results published in a Brickell Biotech Media Release.
    • 20 Feb 2018 According to a Brickell Biotech media release, primary endpoint (Hyperhydrosis severity questionnaire-at least a 1-point improvement in the HDSM-Ax) has been met.
    • 20 Feb 2018 According to a Brickell Biotech media release, data were presented at the 76th American Academy of Dermatology Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top